Canadian Organization for Rare Disorders (CORD)
“My husband and I had the wonderful opportunity to adopt two children, each born with different rare conditions. We had to take charge of our children’s healthcare, but I count among my most significant contributions my decade with the haemophilia community following the tainted blood scandal to gain compensation, reform, and safe therapies, serving as president from 1994-98. My volunteer stint with the Canadian Organization for Rare Disorders began in 2006, when I developed an Orphan Drug Policy and headed the advocacy campaign to access to new therapies. We are encouraged by the significant progress being achieved in rare disease policy, research, services and support in Canada, including the Orphan Drug Regulatory Framework and Canada’s Rare Disease Strategy. In 2012, I transitioned to a part-time paid CEO position.
I joined EURORDIS to learn as much as possible from European initiatives and momentum and Canada has benefited from the association (Canada was the first non-EU country to adopt Rare Disease Day in 2008). I believe strongly in the value of international collaboration (serving on the Board of the International Alliance of Patients’ Organizations and as Chair from 2011-2013); therefore, I chose to take an active role in helping to set up the Asia-Pacific Alliance of Rare Disease Organizations, serving as Secretary of the newly registered alliance.
I have been a member of the interim advisory group of Rare Disease International and believe this network has the opportunity to advance rare diseases globally and especially to ensure that rare disease is addressed in those countries with emerging healthy policy, health and social care, and patient support. I envision RDI as having a key role with international agencies, like the UN and WHO, and also forging international partnerships, including the private sectors. Finally, it is a privilege to be a part of RDI and to help ensure that patient empowerment is a driving component in all of these activities, across disease and geographic boundaries.”
National Organization for Rare Disorders (NORD)
“I have been with the National Organization for Rare Disorders (NORD) for five years, serving as a member of the senior management team in the areas of Membership and Marketing. I am responsible for overseeing the organization’s relationships with patients, families and disease-specific advocacy organizations. In this capacity, I have a very good understanding of the needs and interests of patients and the organizations that represent them here in the United States, and would like to further support them by representing them in this international forum. For the last two years, I have also led the planning and coordination of Rare Disease Day in the United States, successfully activating and engaging advocates in each state to participate in raising rare disease awareness.
I believe I could be an asset to the council given my background in health policy, public health and my experience in designing and managing programs of membership, advocacy, education and capacity building. Having participated on the interim steering council for RDI, I am also aware of its goals, objectives, strengths and challenges. I believe in its mission and the impact it could have on the lives of patients around the world, and am interested in joining the RDI Council to make a meaningful contribution to its short and long-term growth and success.”
Yann Le Cam is a patient advocate who has dedicated 25 years of professional and personal commitment to health and medical research non-governmental organisations in France, Europe and the United States in the fields of cancer, HIV/AIDS and rare diseases.
He has three daughters, the eldest of whom is living with cystic fibrosis. Yann is one of the founders of EURORDIS in 1997 and the organisation’s Chief Executive Officer since 2001.
He has participated in the revision and adoption of European regulations that impact the lives of rare disease patients, including the EU Regulation on orphan medicinal products.
He was one of the first patient representatives appointed to the Committee for Orphan Medicinal Products (COMP) at the European Medicines Agency (EMA), where he served for 9 years and was its vice-chair for 6 years. He served on the Management Board and Executive Committee of the French HTA agency for 5 years, on the DIA Advisory Committee Europe for 3 years.
He was the Vice Chairman of the EU Committee of Experts on Rare Diseases (EUCERD) from 2011 to July 2013, and he is nominated on the current Commission Expert Group on Rare Diseases.
Yann Le Cam is also a member of and immediate past Chair of the Therapies Scientific Committee of IRDIRC (the International Rare Diseases Research Consortium).
In June 2016, Yann Le Cam was elected to the Management Board of the European Medicines Agency
A representative of DEBRA International, Dr Ritu Jain has been an engaged member of the RDI council since 2017. She has actively contributed to drafting RDI’s strategy plans, objectives and bylaws and is working towards strengthening and extending the Rare network in the Asian regions.
Ritu is also president of DEBRA Singapore, the Epidermolysis Bullosa (EB) patient advocacy and support organization that she helped establish in 2015. Within the DEBRA network, she serves as treasurer of DEBRA International and as regional ambassador for EB Without Borders, a Debra International workstream. In all these roles, her focus has been to offer emotional and material support to patients and families, organise local and regional conferences for capacity building and improved delivery of EB care, and advocate for policy changes. She remains committed to fostering collaboration of local and international clinicians/researchers as well as pharmaceutical organisations for enhanced research initiatives and clinical trials for improvement in the quality of lives of individuals living with EB. Ritu’s familiarity with the culture, conditions, and challenges of those with rare diseases in Asia make her a suitable voice within Rare Diseases International for those with rare diseases.
Beyond her volunteer roles, Ritu is a sociolinguist and teaches graduate and under-graduate students at a local university. A PhD from the National University of Singapore, Ritu’s research and publications explore the impact of language policies on languages of immigrant minorities in multilingual sites.
Tsang, a retired business executive with Retinitis Pigmentosa, has been actively volunteering for patients’ groups for some decades, both in Hong Kong and internationally. In March 1995, along with fellow patients, he founded Retina Hong Kong, a self-help organisation for patients with retinal degenerative diseases; he has been the association’s serving President since then.
Kin Ping is also President of the Hong Kong Alliance for Rare Diseases (HKARD; founded in December 2014), the Vice-Chairman of Hong Kong Patients’ Voices (an advocacy platform in the healthcare sector), a board member of AMD Alliance International, and he has been serving on the management committee of Retina International since 2000.
In 2008, he was elected to the Governing Board of the International Alliance of Patients’ Organizations (IAPO) and was the Chair from August 2013 to July 2015.Whilst with IAPO, he has been involved in the planning and organisation of their regional patient workshops in Africa, Latin America and Asia, and the Global Patients Congresses. His main advocating areas are access to treatment, patient safety, drug safety, medical ethics and patient engagement in the healthcare sector.
Additionally, Kin Ping is Vice-President of the Hong Kong Guide Dogs Association and an Honorary Fellow of the Hong Kong Academy of Pharmacy.